Idera Pharmaceuticals Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel(R) in Arthritis Model

Idera Pharmaceuticals announced the presentation of preclinical data from studies of IMO-3100 in combination with Enbrel (etanercept) in a mouse model of arthritis

CAMBRIDGE, MA, USA | October 19, 2009 | Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the presentation of preclinical data from studies of IMO-3100 in combination with Enbrel (etanercept) in a mouse model of arthritis. IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, is a lead drug candidate that Idera is developing for potential applications in autoimmune diseases. Enbrel is an inhibitor of TNF-alpha currently used for the treatment of rheumatoid arthritis. The presentation is being made at the 2009 Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) being held in Philadelphia, PA, October 17-21.

“The data presented today indicate that the combination of IMO-3100 and Enbrel was more effective at ameliorating arthritis symptoms in a commonly used mouse model than was either agent alone,” said Tim Sullivan, Ph.D., Vice President of Development Programs. “These results suggest that combining IMO-3100 with Enbrel holds potential as a combination therapy in rheumatoid arthritis.”

“In addition to the data presented today, we also have observed potent activity of IMO-3100 in other preclinical models of autoimmune diseases including lupus and psoriasis. As a TLR antagonist, IMO-3100 provides a novel mechanism of action relative to other therapeutic approaches to autoimmune diseases, and we intend to submit an Investigational New Drug application to FDA by the end of the year,” said Sudhir Agrawal, D.Phil., Chief Executive Officer and Chief Scientific Officer. “Our first objective in clinical evaluation of IMO-3100 will be to establish safety and to demonstrate the mechanism of action.”

Presentation Number 659 entitled “Studies of Combination of IMO-3100, An Antagonist of TLR7 and TLR9, and Etanercept, a TNF-alpha Inhibitor, in a Mouse Model of Collagen-Induced Arthritis (CIA)” is being presented by Idera scientists today at 9:00 a.m. ET. Data from these studies showed that mice treated with IMO-3100 or Enbrel had lower arthritic scores and less immunological and histological manifestation of arthritis compared to untreated mice. Moreover, mice treated with a combination of IMO-3100 and Enbrel had lower arthritic scores, less inflammation, and less bone pathology as compared to mice treated with either agent alone. The data also showed that the activity of a low Enbrel dosage was markedly enhanced when combined with IMO-3100 in this mouse model.

About IMO-3100

IMO-3100 is a DNA-based compound created through extensive structure-activity relationship studies to function as an antagonist of Toll-like Receptor (TLR) 7 and TLR9. IMO-3100 has been shown in preclinical assays to suppress immune responses mediated through TLR7 and TLR9, including induction of interferon-alpha, TNF-alpha, IP-10, IL-6, and activation of B cells. Studies from independent researchers have suggested that immune complexes involved in certain autoimmune diseases trigger inflammatory immune responses mediated through TLR7 and TLR9. Use of a TLR antagonist to block responses to such immune complexes may provide a novel mechanism of action for potential treatment of autoimmune diseases. IMO-3100 has shown potent activity in mouse models of autoimmune diseases including lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis. The Company continues to evaluate IMO-3100 and other TLR antagonists in additional preclinical models of autoimmune and inflammatory diseases.

IMO-3100 is a lead drug candidate currently in preclinical development. Idera anticipates submitting an Investigational New Drug application for IMO-3100 by the end of 2009.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors (TLRs), which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for our internal development programs and our partnered programs, and generates opportunities for additional collaborative alliances. For more information, visit www.iderapharma.com.

SOURCE: Idera Pharmaceuticals, Inc.

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top